GlassScriptPhysician profile
Kinga Zosia Porter
NPI 1154646099
$4,131.38
in general payments reported to CMS, 2019-2025
35 companies · $484 in 2025
The $484 reported for 2025 was more than what 89% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $387 · 2021: $386 · 2022: $755 · 2023: $1,000 · 2024: $527 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.51 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $568.53 | 2022-2025 | |
| Amgen INC. | $515.23 | 2020-2024 | Repatha, Otezla |
| Currax Pharmaceuticals LLC | $401.59 | 2020-2025 | Contrave, Onzetra Xsail, Nexletol |
| Astrazeneca Pharmaceuticals LP | $385.66 | 2019-2022 | |
| Novo Nordisk INC | $334.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $320.42 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.10 | 2019-2025 | Xifaxan |
| Ibsa Pharma INC. | $143.57 | 2020-2025 | Tirosint, Licart, Licart |
| Davol INC. | $137.82 | 2023 | Phasix Mesh |
| Novartis Pharmaceuticals Corporation | $121.25 | 2019 | |
| Axsome Therapeutics, INC. | $110.89 | 2024-2025 | Auvelity |
| Smith+Nephew, INC. | $102.67 | 2023 | Allevyn Heel 10.5cm X 13.5cm Ctn 5, Collagenase Santyl, Acticoat 4" X 4" |
| Genentech USA, INC. | $99.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $73.47 | 2024 | Xarelto |
| Organon LLC | $68.53 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $61.53 | 2023-2025 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $42.08 | 2020-2021 | |
| Romark Laboratories, Lc | $41.10 | 2019-2020 | |
| Abiomed | $36.48 | 2023 | Impella |
| Astellas Pharma US INC | $32.46 | 2023 | Myrbetriq, Veozah |
| Regeneron Healthcare Solutions, INC. | $25.25 | 2023 | Evkeeza |
| Pfizer INC. | $22.15 | 2025 | |
| Mentor Worldwide LLC | $21.40 | 2019 | |
| Exact Sciences Corporation | $20.57 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $17.25 | 2020 | |
| Paratek Pharmaceuticals, INC. | $17.17 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.95 | 2025 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.89 | 2023 | Jardiance |
| Phadia US INC. | $16.23 | 2022 | |
| Acella Pharmaceuticals, LLC | $15.79 | 2024 | NP Thyroid 60 |
| Optinose US, INC. | $14.68 | 2020 | |
| Avion Pharmaceuticals | $13.70 | 2024 | NP Thyroid 60 |
| Endo Pharmaceuticals INC. | $13.59 | 2019 | |
| Allergan, INC. | $12.71 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinga Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.